Press release
Dilated Cardiomyopathy Therapeutics Market Estimated to Grow According to Forecasts
Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy. For example, in February 2017, Myokardia Inc., a biopharmaceutical company, announced first time administer of MYK-491 to a batch of healthy subjects. MYK-491 is a treatment for dilated cardiomyopathy which is in Phase 1.Read Report Overview - https://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Keen players in the market are also focusing on collaborations, mergers, and acquisitions to consolidate their position. For example, in January 2015, Array BioPharma announced its plans of acquiring and obtaining world rights to encorafenib, which is a late stage oncology product from Novartis Pharma AG.
As per estimates by Transparency Market Research, the global dilated cardiomyopathy therapeutics market will be worth US$328.6 mn by the end of 2020 vis-à-vis revenue, expanding at a CAGR of 4.6% from 2014 to 2020.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2293
Growing Incidence of Cardiac Diseases to Catapult Asia Pacific to Lead Position
The segment of angiotensin II receptor blockers led amongst other drug class segments in 2013. This was followed by the segment of beta blockers. The high acceptance of angiotensin II receptor blocks is attributed to their effective therapeutic action for the treatment of dilated cardiomyopathy.
Geography-wise, the report segments the global dilated cardiomyopathy therapeutics market into: North America, Asia Pacific, Europe, and Rest of the World. North America stood as the leading regional market in 2013 mainly due to high incidence of cardiac diseases. Asia Pacific is expected to take the lead in the upcoming years as changing lifestyle resulting in increasing incidence of cardiac diseases propels growth of dilated cardiomyopathy therapeutics market.
Request for Analysis of COVID-19 Impact on Dilated Cardiomyopathy Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2293
Efforts to Develop Specific Drugs for Dilated Cardiomyopathy Propels Growth
The alarming rise in the prevalence of congestive heart failure is one of the prominent growth drivers of the global dilated cardiomyopathy market. Dilated cardiomyopathy accounts for 30-40% of total number of congestive heart failures each year. As per statistics of the World Health Organization, 17.5 million deaths in 2013 were related to heart disorders. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.
Due to this, several companies have initiated to carry out clinical trials so as to develop drugs specifically for dilated cardiomyopathy. At present, there is not a single FDA approved drug specifically for dilated cardiomyopathy because of which treatment administered is the same as that for congestive heart failure. For example, Array BioPharma is carrying out phase II study for its drug ARRY-371797 for the treatment of dilated cardiomyopathy. In addition, in 2014, Celladon Corporation completed its phase II study of MYDICAR to be used for the treatment of dilated cardiomyopathy. Success of these clinical trials will positively influence the global dilated cardiomyopathy therapeutics market.
Buy Dilated Cardiomyopathy Therapeutics Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=2293<ype=S
Studies reveal that angiotensin receptor blockers such as valsartan can reduce probability of hospitalization by 28%. These drugs have also been effective for patients of systolic heart disease by reduction of deaths by 37% and also for reduced frequency of hospitalization. These factors are furthering the expansion of the global dilated cardiomyopathy therapeutics market.
On the flip side, the side effects of dilated cardiomyopathy therapeutics is leading to their declined use. Moreover, availability of implantable devices and promising gene therapy are acting as roadblocks to the market.
More Trending Reports by Transparency Market Research –
Skilled Nursing Care Services Market: https://www.biospace.com/article/skilled-nursing-care-services-market-a-substantial-increase-in-the-geriatric-population-across-the-globe-has-strengthened-the-market-demand/
Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dilated Cardiomyopathy Therapeutics Market Estimated to Grow According to Forecasts here
News-ID: 2179068 • Views: …
More Releases from Transparency Market Research
Density Gradient Media Market to Reach US$ 4.1 Billion by 2036, Driven by Rapid …
The global density gradient media market was valued at US$ 1.4 Billion in 2025 and is projected to reach US$ 4.1 Billion by 2036, expanding at a robust CAGR of 10.2% from 2025 to 2036. The market's rapid growth is primarily driven by increasing demand for rapid infectious disease screening, expanding cell therapy and immunology research, and continuous technological advancements improving sensitivity and multiplexing in laboratory workflows.
Access key findings and…
Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / …
The global functional coffee market was valued at US$ 21.5 Bn in 2024 and is projected to reach US$ 48.1 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2035. This steady growth trajectory reflects the strong convergence of coffee consumption habits with rising demand for functional and wellness-oriented beverages. Functional coffee has transitioned from a niche category to a mainstream product offering,…
Global Electric Face Cleanser Market Poised for Robust Growth, projected to Reac …
The global electric face cleanser market is witnessing a transformative growth phase as consumers increasingly integrate advanced skincare technologies into their daily routines. Valued at USD 9.8 billion in 2025, the market is projected to expand significantly and reach USD 23.6 billion by 2036, growing at a healthy compound annual growth rate (CAGR) of 8.6% from 2026 to 2036. This growth trajectory underscores the rising importance of personal care technology,…
Asthma and COPD Drugs Market to Reach US$ 82.2 Billion by 2036, Growing at 5.7% …
The global asthma and COPD drugs market demonstrated strong fundamentals in 2025, with a valuation of US$ 44.7 Bn, reflecting the essential and recurring nature of respiratory therapeutics. Supported by a growing patient base and continuous pharmaceutical innovation, the market is projected to reach US$ 82.2 Bn by 2036, expanding at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2036.
This growth trajectory highlights the increasing reliance on…
More Releases for Dilated
Dilated Cardiomyopathy Market Forecast: Trends and Analysis 2024-2031
The "Dilated Cardiomyopathy Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Dilated Cardiomyopathy Market - Rebuilding Hope, Restoring Hearts: Dilated Cardi …
Newark, New Castle, USA: The "Dilated Cardiomyopathy Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Dilated Cardiomyopathy Market: https://www.growthplusreports.com/report/dilated-cardiomyopathy-market/7764
This latest report researches the industry structure, sales, revenue,…
Dilated Cardiomyopathy Market Report, History and Forecast 2022-2030
Dilated Cardiomyopathy Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Dilated Cardiomyopathy industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview…
Global Dilated Cardiomyopathy Market Insights, Forecast
Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of the heart. The global Dilated Cardiomyopathy market is valued at 180 million US$ in 2018 and will reach 290 million US$ by the end…
Dilated Cardiomyopathy Market Opportunity Analysis, 2026 – 2026
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles…
Dilated Cardiomyopathy Therapeutics Market Research Report Forecast
A new market research report has been recently published by Transparency market research, a leading market intelligence firm. The research report, titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, presents a market overview, market drivers, opportunities, challenges, product segmentation, and competitive landscape. The research report also features inputs and recommendations from industry experts and professionals to help the…
